On day 14 post-infection, we reported the effect of ACE2 on the levels of anti-SARS-CoV-2 IgG and IgM antibodies, finding that they were higher in the more severe cases compared to the moderate COVID-19 group. This evidence concerns the gene CD40LG and infection.